HU-210

Effects and research

HU-210, the (–) enantiomer, is an ultrapotent cannabinoid, while its (+) enantiomer HU-211 is not a cannabinoid, but an NMDA antagonist with neuroprotective effects.

HU-210 has an oral LD50 of 5,000 mg/kg in rats and 14,200 mg/kg in rabbits, and an LDLO (lowest lethal dose) of 143 mg/kg in humans. This is more toxic than Δ8-THC; in monkeys and dogs, 9,000 mg/kg of Δ8-THC was nonlethal.

Chemistry

HU-210 is the enantiomer of HU-211 (dexanabinol). The original synthesis of HU-210 is based on an acid-catalyzed condensation of (–)-Myrtenol and 1,1-Dimethylheptylresorcinol (3,5-Dihydroxy-1-(1,1-dimethylheptyl)benzol).

Legal status

HU-210 is not listed in the schedules set out by the United Nations' Single Convention on Narcotic Drugs from 1961 nor their Convention on Psychotropic Substances from 1971, so the signatory countries to these international drug control treaties are not required by said treaties to control HU-210.

New Zealand

HU-210 is banned in New Zealand as of 8 May 2014.

United States

HU-210 is not explicitly listed in the list of scheduled controlled substances in the USA. A brief profile of HU-210 written and published by the Drug Enforcement Administration (DEA) in 2009, but removed in later years, stated that HU-210 is a Schedule I controlled substance under the Controlled Substances Act due to being similar to THC. A version of the document (updated in 2013), now in PDF form, exists on the DEA Office of Diversion Control's website. In that PDF, the DEA reasserts that HU-210 is a Schedule I substance. The DEA currently considers HU-210 a Schedule I controlled substance under the umbrella of ‘tetrahydrocannabinols’ under CSCN 7370.

Alabama

HU-210 is a Schedule I controlled substance in Alabama.

... 9. (6aR, 10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol, some trade or other names: HU-210.}}

Florida

HU-210 is a Schedule I controlled substance, categorized as a hallucinogen, making it illegal to buy, sell, or possess in the state of Florida without a license.

... 47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol].

Vermont

Effective January 1, 2016, HU-210 is a regulated drug in Vermont designated as a "Hallucinogenic Drug."

References

References

1. (January 1990). "Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative". Tetrahedron: Asymmetry.
2. (September 1988). "Enantiomeric cannabinoids: stereospecificity of psychotropic activity". Experientia.
3. (March 1989). "Stereochemical effects of 11-OH-delta 8-THC-dimethylheptyl in mice and dogs". Pharmacology, Biochemistry, and Behavior.
4. (September 1989). "Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-hydroxy-delta 8-tetrahydrocannabinol in rats and pigeons". The Journal of Pharmacology and Experimental Therapeutics.
5. (May 1992). "A novel probe for the cannabinoid receptor". Journal of Medicinal Chemistry.
6. (August 2007). "Medicinal chemistry endeavors around the phytocannabinoids". Chemistry & Biodiversity.
7. (2016). "The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation". Perspectives in Medicinal Chemistry.
8. (2025). "Structural basis of THC analog activity at the Cannabinoid 1 receptor". Nature Communications.
9. (February 1990). "Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor". Neuropharmacology.
10. (October 2003). "Dexanabinol: a novel cannabinoid with neuroprotective properties". IDrugs.
11. "HU-210". Cayman Chemical.
12. (July 1973). "Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys". Toxicology and Applied Pharmacology.
13. "delta-8-Tetrahydrocannabinol". U.S. National Library of Medicine.
14. "International Drug Control Conventions". United Nations Office on Drugs and Crime.
15. "Synthetic cannabinoids: What they are". New Zealand Drug Foundation.
16. "PART 1308 - Section 1308.11 Schedule I". Drug Enforcement Administration, U.S. Department of Justice.
17. "Spice Cannabinoid - HU-210". Drug Enforcement Administration, U.S. Department of Justice.
18. (January 2013). "HU-210". Drug Enforcement Administration, U.S. Department of Justice.
19. (November 2024). "Lists of Scheduling Actions, Controlled Substances, and Regulated Chemicals". Drug and Chemical Evaluation Section, Diversion Control Division, Drug Enforcement Administration Division, U.S. Department of Justice.
20. (March 2014). "Controlled substances, Schedule I, additional synthetic controlled substances and analogue substances included in, trafficking in controlled substance analogues, requisite weight increased, Secs. 13A-12-231, 20-2-23 am'd.". Alabama Senate Bill 333.
21. "Chapter 893: Drug Abuse Prevention and Control". The Florida Legislature.
22. (15 July 2017). "Code of Vermont Rules". Vermont Department of Health.